Global Central Nervous System Diseases Drug Delivery Markets, Technology, & Competitive Landscape Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Drug Delivery in Central Nervous System Diseases – Technologies, Markets & Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

Profiles of 77 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 101 collaborations. These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery. A number of cell and gene therapy companies with products in development for CNS disorders are included. References contains over 420 publications that are cited in the report.

Among the three main approaches to drug delivery to the CNS – systemic administration, injection into CSF pathways, and direct injection into the brain – the greatest developments is anticipated to occur in the area of targeted delivery by systemic administration.

Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described.

The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.

The method of delivery of a drug to the CNS has an impact on the drug’s commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2020, projections are made to the years 2025 and 2030. The market values are tabulated according to therapeutic areas, technologies and geographical areas.

Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides the development of new products, these include the application of innovative methods of delivery to older drugs to improve their action and extend their patent life.

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.

Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid the development of drugs that fail to reach their target site of action in the CNS.

Various strategies that have been used for manipulating the blood-brain barrier for drug delivery to the brain include osmotic and chemical opening of the blood-brain barrier as well as the use of transport/carrier systems. Other strategies for drug delivery to the brain involve bypassing the BBB.

Various pharmacological agents have been used to open the BBB and direct invasive methods can introduce therapeutic agents into the brain substance. It is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS.

Various routes of administration as well as conjugations of drugs, e.g., with liposomes and nanoparticles, are considered. Some routes of direct administration to the brain are non-invasive such as transnasal route whereas others involve entry into the CNS by devices and needles such as in case of intrathecal and intracerebroventricular delivery. Systemic therapy by oral and parenteral routes is considered along with the sustained and controlled release to optimize the CNS action of drugs.

Markets for Drug Delivery in CNS Disorders

• Methods of calculation of CNS drug delivery markets
• Markets for CNS drug delivery technologies
• Drug delivery share in selected CNS markets
• CNS share of drug delivery technologies
• Geographical distribution of CNS drug delivery markets
• Impact of improved drug delivery on CNS drug markets
• Neurodegenerative disorders
• Alzheimer disease
• Parkinson disease
• Huntington disease
• Amyotrophic lateral sclerosis
• Epilepsy
• Migraine and other headaches
• Stroke
• Central nervous system trauma
• Multiple sclerosis
• Brain tumors
• Limitations of the current drug delivery technologies for CNS
• Unmet needs in CNS drug delivery technologies
• Regulatory considerations for drugs that cross the BBB
• Public-private collaboration for transfer of research to the clinic
• Future strategies for expanding CNS drug delivery markets
• Education of neurologists
• Demonstration of the advantages of the newer methods of delivery
• Rescue of old products by novel drug delivery methods
• Facilitation of the approval process of new drugs

Basics of Drug Delivery to the Central Nervous System

• Historical evolution of drug delivery for CNS disorders
• Neuroanatomical and neurophysiological basis of drug delivery
• The cerebrospinal fluid
• The lymphatic drainage system of the brain
• The extracellular space in the brain
• Neurotransmitters
• Extracellular vesicles as drug delivery vehicles
• Neuropharmacology relevant to drug delivery
• Introduction to neuropharmacology
• Pharmacokinetics
• Absorption and distribution of drugs
• Drug metabolism and elimination
• Pharmacodynamics
• Receptors
• Sites of drug action in the CNS
• Receptors coupled to guanine nucleotide binding proteins
• Acetylcholine receptor channels
• Dopamine receptors
• GABA receptor channels
• Glutamate receptor channels
• Non-competitive NMDA antagonists
• Serotonin receptors
• G-protein coupled receptors
• In vivo study of drug action in the CNS in human patients
• Electroencephalography
• Brain imaging
• Chronopharmacology as applied to the CNS
• Role of drug delivery in personalized therapy of CNS disorders

Key Topics Covered:

Executive Summary

1. Basics of Drug Delivery to the Central Nervous System

2. Blood Brain Barrier

3. Methods of Drug Delivery to the CNS

4. Delivery of Cell, Gene and Antisense Therapies to the CNS

5. Drug Delivery for Treatment of Neurological Disorders

6. Drug delivery for brain tumors

7. Markets for Drug Delivery in CNS Disorders

8. Companies

9. References

For more information about this report visit https://www.researchandmarkets.com/r/coq1p9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900